Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab

A10.06 Detecting adalimumab serum level and anti-drug antibodies – future tool in monitoring spondyloarthritis patients?

(2016) C Deaconu et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0385 Immunogenicity, Tnf-Inhibitors Levels and Disease Outcomes in Ankylosing Spondylitis: Results from An Observational Cohort Study

(2016) C. Ancuta et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0140 Efficacy and Safety Analysis by Overall anti-Drug Antibody Results Up To Week 30 in Patients with Rheumatoid Arthritis Treated with Sb2 (An Infliximab Biosimilar) or Infliximab Reference Product in Phase III Study

(2016) J.-Y. Choe et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0881 Anti-Adalimumab Antibodies in Juvenil Idiopathic Arthritis and Loss of Response. Preliminary Study

(2016) S. Masegosa et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0129 Clinical Outcomes of Immunogenicity in Rheumatoid Arthritis Patients under anti-TNF Biologics: Results from An Observational Study

(2016) C. Ancuta et al.   ANNALS OF THE RHEUMATIC DISEASES

Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn’s disease patients treated with infliximab

(2016) B. Hernández-Breijo et al.   BIOCHEMICAL PHARMACOLOGY

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2016) Bella Ungar et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

(2016) Johannan F. Brandse et al.   Clinical Gastroenterology and Hepatology

Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels

(2016) Ashley Bond et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Sa1968 Post-Induction Adalimumab Drug Levels Predict Clinical and Laboratory Remission at Week 24 in Patients With Crohn's Disease

(2016) Eran Zittan et al.   GASTROENTEROLOGY

Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohnʼs Disease

(2016) Ronen Stein et al.   INFLAMMATORY BOWEL DISEASES

Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis

(2016) Andres J. Yarur et al.   INFLAMMATORY BOWEL DISEASES

The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study

(2016) Ariela Hoxha et al.   JOINT BONE SPINE

Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease

(2016) Casper Steenholdt et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

DOP066. Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease

(2016)   Journal of Crohns & Colitis

Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn’s Disease

(2016) E. Zittan et al.   Journal of Crohns & Colitis

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response

(2016) Maria Sole Chimenti et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease

(2016) Phillip Minar et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis

(2016) N.M. Mostafa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort

(2016) Yuki Ishikawa et al.   PLoS One

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

(2016) Joana Afonso et al.   Therapeutic Advances in Gastroenterology

Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study

(2016) Grith Petersen Eng et al.   PLoS One

Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis

(2015) H Chiu et al.   ACTA DERMATO-VENEREOLOGICA

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

(2015) D. J. Buurman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

AB0419 Determination of Anti-Drug Antibodies in Long-Term Treatment of Rheumatoid Arthritis Patients with Etanercept

(2015) S. Drynda et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0152 A Randomised, Double-Blind, Phase III Study Comparing SB2, An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

(2015) J.-Y. Choe et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0749 Is There Any Causal Relationship Between Infliximab Immunogenicity and Auto-Antibody Formation in Ankylosing Spondylitis Patients with Secondary Infliximab Treatment Failure

(2015) O. Rumyantseva et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

(2015) Sarah S. Thomas et al.   BIODRUGS

Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility

(2015) Meenu Wadhwa et al.   BIOLOGICALS

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

(2015) B. Rup et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

(2015) Henit Yanai et al.   Clinical Gastroenterology and Hepatology

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease

(2015) David Drobne et al.   Clinical Gastroenterology and Hepatology

Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting

(2015) Andrea Warman et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Tu1292 Quantification of the Concentration of Antibodies Against Infliximab (IFX) in Human Serum Using a Pure Antibody As Calibrator

(2015) Borja Hernandez-Breijo et al.   GASTROENTEROLOGY

Tu1308 Adequate Trough Concentrations and Sustained TNF Suppression Early on During Induction Therapy With Adalimumab Predict Remission in Anti-TNF Naïve Crohn's Disease Patients

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Tu1315 Loss of Response in IBD Patients on Infliximab Treatment: Assay of Infliximab Trough Levels and Total Antibodies to Infliximab

(2015) Luisa Guidi et al.   GASTROENTEROLOGY

Su1206 Association Between Crohn's Disease Activity and Therapeutic Drug Monitoring of Thiopurines and Infliximab Comparing Free and Total Antidrug Antibody Measurement

(2015) Mark G. Ward et al.   GASTROENTEROLOGY

PTU-078 A prospective evaluation of adalimumab drug levels and anti-drug antibodies using two commercial elisa and the influence of 6-thioguanine nucleotides amongst patients with inflammatory bowel disease:

(2015) EL Johnston et al.   GUT

Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial

(2015) Filip Baert et al.   GUT

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

(2015) Shomron Ben-Horin et al.   GUT

Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD

(2015) Naamah L. Zitomersky et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases

(2015) Andres J. Yarur et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease

(2015) Shringi Sharma et al.   INFLAMMATORY BOWEL DISEASES

An Examination of the Mechanisms Involved in Secondary Clinical Failure to Adalimumab or Etanercept in Inflammatory Arthropathies

(2015) Sara Bandrés Ciga et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

P473. Antibodies to infliximab, body weight and low serum albumin levels increase clearance of infliximab, a population pharmacokinetic study in 324 IBD patients

(2015)   Journal of Crohns & Colitis

OP006. Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary non-response to infliximab in Crohn's disease patients

(2015)   Journal of Crohns & Colitis

P324. Biomarkers predict lack of response to anti-TNF in Moderate to Severe Ulcerative Colitis

(2015)   Journal of Crohns & Colitis

P486. Assay of infliximab trough levels and of total antibodies to infliximab in the management of loss of response

(2015)   Journal of Crohns & Colitis

P526. Impact of postinduction infliximab trough level and disease activity on primary response in Crohn's Disease

(2015)   Journal of Crohns & Colitis

P561. Time course and clinical implications of development of binding and neutralizing antibodies against adalimumab in patients with inflammatory bowel disease

(2015)   Journal of Crohns & Colitis

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

(2015) Taku Kobayashi et al.   JOURNAL OF GASTROENTEROLOGY

Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure

(2015) Bella Ungar et al.   MEDICINE

The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease

(2015) Daniël R. Hoekman et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response

(2015) A Skrabl-Baumgartner et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNFαBlockers in Rheumatoid Arthritis and Spondyloarthritis Patients

(2015) Inesa Arstikyte et al.   Biomed Research International

Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis

(2015) Meghna Jani et al.   Arthritis & Rheumatology

Tu1147 Serum Adalimumab Levels and Antibodies Correlate With Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients With Inflammatory Bowel Disease

(2015) Andres J. Yarur et al.   GASTROENTEROLOGY

Tu1150 Association of Serum Infliximab and Antibodies to Infliximab to Long-Term Clinical Outcome and Mucosal Healing in Crohn's Disease

(2015) Ofer Ben-Bassat et al.   GASTROENTEROLOGY

Tu1135 Serum Adalimumab and Immunogenicity in IBD Patients After 80mg Biweekly Maintenance Therapy

(2015) Ofer Ben-Bassat et al.   GASTROENTEROLOGY

Su1192 A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab

(2015) Douglas C. Wolf et al.   GASTROENTEROLOGY

94 Treatment of Secondary Infliximab Failure in Crohn's Disease Based on Serum Levels of Infliximab and Antibodies Against Infliximab: The Danish Study of Optimizing Infliximab Therapy in Crohn's Disease (Do It Crohn) Randomized Clinical Trial

(2015) Casper Steenholdt et al.   GASTROENTEROLOGY

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

(2014) B. G. Levesque et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

AB0278 Prolonging between-infusions interval is associated with positivity to anti-infliximab antibodies in rheumatoid arthritis and spondyloarthritis patients

(2014) M. Verdet et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0197 Presence of Antibodies to Adalimumab and Infliximab in Patients with Rheumatoid Arthritis in Clinical Remission

(2014) G. Eng et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0206 Clinical Usefulness of Serum Level of Adalimumab, in Patients with Rheumatoid Arthritis

(2014) J. Rosas et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0175 Anti-drug-antibodies but not igg-4 antibodies against tnf blockers influence the activity of anti-tnf drugs in rheumatoid arthritis

(2014) M. Benucci et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0171 Influence of Immunogenicity of Anti-TNF Therapy in RA Patients with a Long-Term Treatment with Infliximab or Adalimumab

(2014) A. Villalba et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0219 The Infliximab Dose Increase is Not Correlated with Clinical Improvement in RA Patients

(2014) M. T. López-Casla et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0497 Simultaneous determination of anti-infliximab antibodies and residual infliximab levels to monitor anti-TNF therapy

(2014) S. Chollet-Martin et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study

(2014) D. H. Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis

(2014) Der-Yuan Chen et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up

(2014) Erik H Vogelzang et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0265 Immunogenicity of Anti-TNF Antagonists in Patients with Rheumatoid Arthritis or Polyarticular Psoriatic Arthritis in Clinical Remission or Low Disease Activity: The Inmunoremar Study: Table 1

(2014) R. Sanmarti et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0391 A Diminished Clinical Response at 28 and 52 Weeks of Adalimumab Treatment in Patients with Psoriatic Arthritis is Associated with Anti-Drug Antibodies

(2014) E. Vogelzang et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0052 Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A Uk-Based Prospective Study

(2014) M. Jani et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0159 Disease Activity Assessment Using the DAS28, CDAI and SDAI and Effect of Anti-Drug Antibody on Clinical Response in a Randomized, Double-Blind, Comparative Trial of CT-P13 and Innovator Infliximab: Planetra Study

(2014) D.-H. Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0371 Clinical Significance of Anti-Adalimumab Antibodies in Rheumatoid Arthritis, Ankylosing Spondilitis and Psoriasic Arthritis

(2014) A. Hoxha et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0370 Association of Clinical Efficacy with Serum Level of Adalimumab (ADA) and Anti- Adalimumab Antibody Levels in Patients with Early Rheumatoid Arthritis (RA)

(2014) A.S. Avdeeva et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0346 Anti-Drug Antibodies as A Predictor for the Discontinuation of Anti-TNF Agents in Patients with Spondyloarthrtis

(2014) H.J. Kim et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0331 Effect of Methotrexate on the Immnunogenicity of TNF Inhibitors in Spondyloartrhitis Patients

(2014) A. Villalba Yllan et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0253 The Early Infliximab Levels Monitoring Can Predict the Developement of Anti-Drug Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab:

(2014) P.-R. Chamaida et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0164 Tnf-Alpha Bioactivity: A New Biomarker of Aspa Activity in Patients with Tnf-Alpha Blockers

(2014) E. Constant et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0157 Clinical Response of Disease Activity, Disability and Mobility Indices in Relation to Anti-Drug Antibody in the Planetas

(2014) W. Park et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0288 Immunogenicity is Associated with Lupus-Like Autoimmunity in Rheumatoid Arthritis Patients Treated with Infliximab

(2014) Y. Ishikawa et al.   ANNALS OF THE RHEUMATIC DISEASES

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

(2014) Filip Baert et al.   Clinical Gastroenterology and Hepatology

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years

(2014) Daniel J. Kingsbury et al.   CLINICAL RHEUMATOLOGY

Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study

(2014) Roy Fleischmann et al.   CURRENT MEDICAL RESEARCH AND OPINION

Detection of Adalimumab and Anti-Adalimumab Levels by ELISA: Clinical Considerations

(2014) Barbara Marinari et al.   DRUG DEVELOPMENT RESEARCH

786 The Pharmacokinetics of Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

(2014) Johannan F. Brandse et al.   GASTROENTEROLOGY

Tu1202 Correlation Between Infliximab Levels (IFX) and Antibody to Infliximab (ATI) in Pediatric Patients With Inflammatory Bowel Disease (IBD) With the Commercially Available Assay Using Electrochemilumescense

(2014) Edgardo D. Rivera Rivera et al.   GASTROENTEROLOGY

Sa1247 Antibodies to Adalimumab Predict Inflammation in Crohn's Patients on Maintenance Adalimumab Therapy

(2014) Filip J. Baert et al.   GASTROENTEROLOGY

Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohnʼs Disease

(2014) Peter C. Church et al.   INFLAMMATORY BOWEL DISEASES

Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease

(2014) Namita Singh et al.   INFLAMMATORY BOWEL DISEASES

Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis

(2014) Seung Min Jung et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

P-112: The association between drug levels, anti-drug antibodies, and therapeutic response during infliximab therapy in pediatric Crohn’s disease

(2014) R.E. Stein et al.   Journal of Crohns & Colitis

Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment

(2014) Per Marits et al.   Journal of Crohns & Colitis

DOP057 The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF-α levels and clinical outcome

(2014) G. Bodini et al.   Journal of Crohns & Colitis

P444 Infliximab trough levels and antibodies: relationship with infusion reaction, immunomodulators and biological parameters

(2014) M.D. Martin Arranz et al.   Journal of Crohns & Colitis

Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease

(2014) Maria Hukkinen et al.   Journal of Crohns & Colitis

Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis

(2014) Michael J Hayes et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

(2014) Nobuyuki Miyasaka et al.   Modern Rheumatology

Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis

(2014) Motoaki Hoshino et al.   Modern Rheumatology

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease

(2014) Éva Pallagi-Kunstár   WORLD JOURNAL OF GASTROENTEROLOGY

Lack of Anti-drug Antibodies in Patients with Psoriasis Well-controlled on Long-term Treatment with Tumour Necrosis Factor Inhibitors

(2013) M Meyer et al.   ACTA DERMATO-VENEREOLOGICA

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies

(2013) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up

(2013) Eva L Kneepkens et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation

(2013) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study

(2013) S.K. Mahil et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)

(2013) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis

(2013) T. Bito et al.   BRITISH JOURNAL OF DERMATOLOGY

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2013) Xavier Roblin et al.   Clinical Gastroenterology and Hepatology

Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

(2013) C. C. Mok et al.   CLINICAL RHEUMATOLOGY

Impact of measurement of infliximab and anti-infliximab antibodies levels in pediatric inflammatory bowel disease

(2013) S. Cardile et al.   DIGESTIVE AND LIVER DISEASE

P.08.7 CLINICAL IMPLICATIONS AND STABILITY OF DETERMINATION OF INFLIXIMAB TROUGH LEVELS (IFX-TL) AND ANTIBODIES TO INFLIXIMAB (ATI) IN INFLAMMATORY BOWEL DISEASE

(2013) M. Daperno et al.   DIGESTIVE AND LIVER DISEASE

Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

(2013) Bella Ungar et al.   GUT

Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

(2013) Stephane Paul et al.   INFLAMMATORY BOWEL DISEASES

P551 Detection of anti infliximab antibodies in patients with inflammatory bowel disease (IBD) in the presence of infliximab by homogeneous liquid phase anti infliximab mobility shift assay

(2013) A. Eser et al.   Journal of Crohns & Colitis

P274 Clinical utility of measuring serum TNF alpha level, anti TNF alpha levels and antibody titers in critical situations in inflammatory bowel disease and in psoriasis

(2013) Z. Szepes et al.   Journal of Crohns & Colitis

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease

(2013) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

(2013) Yasuo Suzuki et al.   JOURNAL OF GASTROENTEROLOGY

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure

(2013) S. B. Krintel et al.   RHEUMATOLOGY

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

(2013) Chamaida Plasencia et al.   ARTHRITIS RESEARCH & THERAPY

Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis

(2013) Stef P. Menting et al.   JAMA Dermatology

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab

(2012) Chamaida Plasencia et al.   ANNALS OF THE RHEUMATIC DISEASES

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis

(2012) Thierry Dervieux et al.   ANNALS OF THE RHEUMATIC DISEASES

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

(2012) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

(2012) Aatke van der Maas et al.   BMC MUSCULOSKELETAL DISORDERS

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan

(2012) Tomoyuki Imagawa et al.   CLINICAL RHEUMATOLOGY

Early Infliximab Trough Levels Predict Remission at one Year in Pediatric IBD Patients

(2012) Casey Rosenthal et al.   INFLAMMATORY BOWEL DISEASES

OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial

(2012) N. Vande Casteele et al.   Journal of Crohns & Colitis

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

(2012) Martin Bortlik et al.   Journal of Crohns & Colitis

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

(2011) T. Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study

(2011) L. A. Korswagen et al.   ARTHRITIS AND RHEUMATISM

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

(2011) Bart JF van den Bemt et al.   BMC MUSCULOSKELETAL DISORDERS

Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction

(2011) J.H.O. Hoffmann et al.   BRITISH JOURNAL OF DERMATOLOGY

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

(2011) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease

(2011) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

(2011) D. Pascual-Salcedo et al.   RHEUMATOLOGY

Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study

(2011) Jean-Camille Méric et al.   THERAPEUTIC DRUG MONITORING

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

(2011) Geertje M Bartelds et al.   ARTHRITIS RESEARCH & THERAPY

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

(2011) Suzanne Arends et al.   ARTHRITIS RESEARCH & THERAPY

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

(2011) Emilie Ducourau et al.   ARTHRITIS RESEARCH & THERAPY

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

(2010) A. W. R. van Kuijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Fc  receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis

(2010) A. Okuyama et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

(2010) N. Ruperto et al.   ANNALS OF THE RHEUMATIC DISEASES

Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis

(2010) Lidian L. A. Lecluse et al.   ARCHIVES OF DERMATOLOGY

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

(2010) S. Ben-Horin et al.   GUT

Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients

(2010) Axel Finckh et al.   JOINT BONE SPINE

Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study

(2010) Esra ADIŞEN et al.   JOURNAL OF DERMATOLOGY

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

Monitoring of anti-TNF biological treatments

(2010) A Ruiz del Agua et al.   Journal of Translational Medicine

The safety and side effects of monoclonal antibodies

(2010) Trevor T. Hansel et al.   NATURE REVIEWS DRUG DISCOVERY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

(2009) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

(2008) T R D J Radstake et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

(2008) Jürgen Braun et al.   ARTHRITIS AND RHEUMATISM

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

(2008) Arie E. van der Bijl et al.   CLINICAL RHEUMATOLOGY

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

(2008) Gopi Shankar et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

(2007) Mark A. Ainsworth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY